Millie Capital Management LLC Acquires Shares of 1,130 Biogen Inc (BIIB)

Millie Capital Management LLC acquired a new position in shares of Biogen Inc (NASDAQ:BIIB) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,130 shares of the biotechnology company’s stock, valued at approximately $360,000.

Other institutional investors also recently made changes to their positions in the company. Atlantic Trust LLC purchased a new position in Biogen during the second quarter worth approximately $114,000. Harel Insurance Investments & Financial Services Ltd. lifted its position in Biogen by 77.0% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock worth $127,000 after buying an additional 174 shares in the last quarter. Horan Capital Advisors LLC. purchased a new position in Biogen during the third quarter worth approximately $128,000. Massey Quick Simon & CO. LLC lifted its position in Biogen by 84.8% during the third quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock worth $133,000 after buying an additional 195 shares in the last quarter. Finally, Gs Investments Inc. purchased a new position in Biogen during the second quarter worth approximately $136,000. Hedge funds and other institutional investors own 88.11% of the company’s stock.

In related news, Director Alexander J. Denner bought 30,000 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was purchased at an average cost of $317.36 per share, with a total value of $9,520,800.00. Following the purchase, the director now directly owns 10,029 shares of the company’s stock, valued at approximately $3,182,803.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Robert W. Pangia sold 5,832 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total value of $1,922,518.80. Following the transaction, the director now directly owns 23,539 shares of the company’s stock, valued at $7,759,631.35. The disclosure for this sale can be found here. Insiders have purchased a total of 31,560 shares of company stock valued at $10,020,858 over the last three months. 0.25% of the stock is currently owned by insiders.

BIIB has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $363.00 price objective (up previously from $340.00) on shares of Biogen in a research report on Friday, January 26th. Citigroup reiterated an “outperform” rating and set a $380.00 price objective (up previously from $350.00) on shares of Biogen in a research report on Tuesday, January 16th. Mizuho set a $400.00 price objective on Biogen and gave the stock a “buy” rating in a research report on Thursday, January 18th. Jefferies Group reiterated a “hold” rating on shares of Biogen in a research report on Friday, January 26th. Finally, Cantor Fitzgerald reiterated a “hold” rating and set a $279.00 price objective on shares of Biogen in a research report on Tuesday, October 24th. Eight investment analysts have rated the stock with a hold rating and twenty-four have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $368.99.

Shares of Biogen Inc (NASDAQ BIIB) opened at $312.77 on Friday. Biogen Inc has a one year low of $244.28 and a one year high of $370.57. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $69,157.73, a price-to-earnings ratio of 26.16, a PEG ratio of 1.70 and a beta of 0.75.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). Biogen had a net margin of 20.69% and a return on equity of 38.32%. The firm had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. During the same period in the previous year, the firm posted $5.04 earnings per share. The company’s quarterly revenue was up 15.1% compared to the same quarter last year. sell-side analysts predict that Biogen Inc will post 24.88 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://sportsperspectives.com/2018/02/09/millie-capital-management-llc-acquires-shares-of-1130-biogen-inc-biib.html.

Biogen Company Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply